Abstract:The poor ability of recognition and penetration of chemotherapeutic agents to tumor cells are still great challenges for targeted breast cancer treatment. Herein, we established a tumor-targeted nanostructured lipid carrier encapsulating gambogic acid (GA) and paclitaxel (PTX), which was co-modified with acid-cleavable folic acid (cFA) and a human-derived cell penetrating peptide dNP2 (CKIKKVKKKGRKKIKKVKKKGRK). The multi-functional nano-platform exhibited an enhanced targeting and penetrability to tumor tissues, which was accomplished by the combined action of cFA and dNP2. After intravenous injection, firstly, cFA could actively target the breast cancer tissues by the selective recognition of folate receptor (FR); then, upon arrival at the tumor microenvironment, the acid-cleavable FA and dNP2 dual modified nanostructured lipid carrier (cFA/dNP2-GA/PTX-NLC) exhibited sensitive cleavage of folic acid (FA), which could reduce the hindrance effect of FA to maximize the dNP2 cell-penetrating properties. The effect of different modification on cellular uptake, in vivo bio-distribution, and anticancer activity of NLCs proved our hypothesis that compared with NLCs modified by non-cleavable FA or a single ligand, cFA/dNP2-GA/PTX-NLC displayed more efficient intracellular delivery, stronger targeting ability in vivo, improved cytotoxicity on 4T1 cells, and produced the better therapeutic efficacy of GA and PTX. The strategy affords a feasible way to overcome the poor recognition and permeability of medicines in cancer treatment.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to solve the problem of insufficient ability of chemotherapy drugs to identify and penetrate tumor cells in breast cancer treatment. Specifically, the research team developed a dual - drug - loaded self - assembled nanostructured lipid carrier (NLC), and modified it with acid - responsive folic acid (cFA) and human - derived cell - penetrating peptide dNP2 to improve its targeting and permeability to tumor tissues. ### Background and challenges 1. **Limitations of chemotherapy drugs**: - Chemotherapy drugs lack specificity and targeting, are likely to act on normal tissues and cells, resulting in low drug efficacy and significant side effects. - The metastasis of cancer cells and multidrug resistance (MDR) further hinder the successful treatment of breast cancer. 2. **Advantages of multi - drug combination therapy**: - The combined use of multiple anti - tumor active ingredients has become the preferred option for tumor treatment, showing a good synergistic effect. - Studies have shown that the combined use of gabu acid (GA) and paclitaxel (PTX) can reverse the multidrug resistance of PTX and inhibit the migration and invasion of cancer cells, thereby improving the treatment effect. 3. **Application of nano - carrier systems**: - Nanostructured lipid carriers (NLC) have good biocompatibility and high drug - loading capacity, and can achieve slow - release and stability of drugs. - Cell - penetrating peptides (CPP) such as dNP2 can effectively penetrate cell membranes and enter the interior of cells, improving the anti - tumor effect of drugs. ### Solutions 1. **Design of dual - drug - loaded NLC**: - Developed an NLC loaded with GA and PTX, which was modified with acid - responsive folic acid (cFA) and cell - penetrating peptide dNP2. - cFA can be cleaved under acidic conditions in the tumor microenvironment, exposing dNP2, thereby enhancing the cell - penetrating ability of NLC. 2. **Experimental verification**: - Through in vitro cell experiments and in vivo animal experiments, the cell uptake, biodistribution and anti - cancer activity of cFA/dNP2 - GA/PTX - NLC were verified. - The results showed that compared with unmodified or single - modified NLC, cFA/dNP2 - GA/PTX - NLC exhibited higher intracellular delivery efficiency, stronger targeting ability and better treatment effect. ### Main conclusions This study successfully developed a dual - drug - loaded self - assembled nanostructured lipid carrier. Through the dual modification of acid - responsive folic acid and cell - penetrating peptide, the ability of drugs to identify and penetrate breast cancer cells was significantly improved, providing a new strategy for the treatment of breast cancer.

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer.

Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy

Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy.

The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with High-Affinity Peptides Discovered by Phage Display.

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Targeting and microenvironment-responsive lipid nanocarrier for the enhancement of tumor cell recognition and therapeutic efficiency.

Stromal Barrier-Dismantled Nanodrill-Like and Cancer Cell-Targeted Ph-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin

Chemotherapeutic Drug Delivery to Cancer Cells Using a Combination of Folate Targeting and Tumor Microenvironment-Sensitive Polypeptides.

Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model

A Nanosized Codelivery System Based on Intracellular Stimuli-Triggered Dual-Drug Release for Multilevel Chemotherapy Amplification in Drug-Resistant Breast Cancer

Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages

Dual tumor-targeted poly(lactic-co-glycolic acid)-polyethylene glycol-folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery.

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals

Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy

Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach

Procedurally Targeted Delivery of Antitumor Drugs Using FAPα-Responsive TPGS Dimer-Based Flower-like Polymeric Micelles.

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane